Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Experimental Group:Conventional Treatment & Low Dose Recombinant Human Interleukin-2, i.m.(1 million IU per time, once another day, 3 times per week, 2 weeks)
Control Group:Conventional Treatment+Placebo i.m.(once another day, 3 times per week, 2 weeks)
Sponsors
Renmin Hospital of Wuhan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Those who meet the diagnosis of new coronavirus pneumonia and have clinical classification of low and medium; (2) Inpatients aged 18 to 75 years; (3) Voluntarily receive treatment with the drug and sign informed consent. The informed consent process complies with relevant GCP regulations.
Exclusion criteria
Exclusion criteria: (1) Immunodeficiency disease, or those who have used immunosuppressive agents or glucocorticoids within the past 3 months; (2) Preparing pregnant, pregnant and lactating women; (3) Patients with allergies (referring to allergies to two or more medicines, foods or known ingredients in this study); (4) Patients with mental illness, or have no cognitive ability; (5) Patients with an estimated survival time of less than 48 hours from the start of screening; (6) Those who have been intubated or mechanically ventilated at the time of screening; (7) Obvious symptoms of heart, liver, kidney or various other systems, ALT, AST exceed 1.5 times the upper limit of normal value; (8) Believed to be not suitable to participate in clinical trials by investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CD8+ T cells numbers;CD4+ T cell numbers;NK cell numbers;Fatality rate;Clinical recovery time;Critical (severe or critical) conversion rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Arterial Oxygen Saturation;cytokines/chemokines;Hospital stay duration;Inflammation index (CRP); | — |
Countries
China
Contacts
Public ContactQianxue Chen
Renmin Hospital of Wuhan University
Outcome results
None listed